DNDi-CPG-01

Participant Flow:



Baseline Characteristics:

Summary of Subject Demographics (Safety Set)

Parameter	Statistic	Placebo (N=6)	Cohort 1: 7.5 mg CpG ODN D35 (N=6)	Cohort 2: 22.5 mg CpG ODN D35 (N=6)	Cohort 3: 67.5 mg CpG ODN D35 (N=6)	CpG ODN D35 Overall (N=18)	Overall (N=24)
Gender							
Male		6	6	6	6	18	24
Female		0	0	0	0	0	0
Age (yrs)	Mean	32.7	32.3	32.3	36.7	33.8	33.5
	SD	6.25	8.89	5.16	9.37	7.83	7.35
Height (m)	Mean	1.760	1.763	1.750	1.768	1.761	1.760
	SD	0.0687	0.0728	0.0438	0.0397	0.0515	0.0547
Weight (kg)	Mean	79.18	77.37	79.22	76.90	77.83	78.17
	SD	5.916	7.455	4.400	5.424	5.635	5.607
BMI (kg/m^2)	Mean	25.585	24.995	25.875	24.603	25.158	25.265
	SD	1.6625	3.2468	1.3241	1.7552	2.1958	2.0495
Ethnicity							
Not hispanic or latino	n (%)	6 (100)	6 (100)	6 (100)	6 (100)	18 (100)	24 (100)
Hispanic or latino	n (%)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Race							
Black or African American	n (%)	1 (16.7)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	1 (4.2)
American Indian or Alaska Native	n (%)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Asian	n (%)	0 (0.0)	1 (16.7)	0 (0.0)	0 (0.0)	1 (5.6)	1 (4.2)
Native Hawaiian or Other Pacific Islander	n (%)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
White	n (%)	4 (66.7)	5 (83.3)	5 (83.3)	6 (100)	16 (88.9)	20 (83.3)
Mixed	n (%)	1 (16.7)	0 (0.0)	1 (16.7)	0 (0.0)	1 (5.6)	2 (8.3)
Other	n (%)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)

Percentages are calculated from the number of subjects in the Safety Set within a treatment group.
BMI = body mass index.

Outcome Measures:

Primary outcome

Overall Summary of TEAEs by Severity and Relationship (Safety Set)

	Placebo (N=6)	Cohort 1: 7.5 mg CpG ODN D35 (N=6)	Cohort 2: 22.5 mg CpG ODN D35 (N=6)	Cohort 3: 67.5 mg CpG ODN D35 (N=6)	CpG ODN D35 Overall (N=18)	Overall (N=24)
Number of TEAEs	0	10	8	21	39	39
Number (%) of subjects reporting at least one:						
TEAE	0 (0.0)	6 (100.0)	6 (100.0)	6 (100.0)	18 (100.0)	18 (75.0)
Serious TEAE	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
TEAE Leading to Withdrawal	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
TEAE Leading to Death	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Number (%) of subjects with TEAE by severity:						
Mild	0 (0.0)	5 (83.3)	3 (50.0)	4 (66.7)	12 (66.7)	12 (50.0)
Moderate	0 (0.0)	1 (16.7)	3 (50.0)	2 (33.3)	6 (33.3)	6 (25.0)
Severe	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Life-threatening	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Death	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Number (%) of subjects with TEAE by relationship to study drug:						
Definitely related	0 (0.0)	6 (100.0)	6 (100.0)	6 (100.0)	18 (100.0)	18 (75.0)
Probably related	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Possibly related	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Probably not related	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Not related	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)

Treatment: A single subcutaneous dose of 7.5 mg CpG ODN D35 (Cohort 1), 22.5 mg CpG ODN D35 (Cohort 2), 67.5 mg CpG ODN D35 (Cohort 3) or placebo.
Percentages are calculated from the number of subjects in the Safety Set within a treatment group.
A subject with multiple adverse events is counted only once at the maximum level of severity or the strongest relationship to study drug.
TEAE = treatment emergent adverse event

Secondary outcome measures

Summary of Derived CpG ODN D35 PK Parameters (PK Set)

PK Parameter	Summary Statistic	CpG ODN D35 (Single Dose)	
		22.5 mg (N=4)	67.5 mg (N=6)
C_{max} (ng/mL)	n	4	6
	Geo. Mean	33.1	134
	CV%	41.9	46.5
T_{max} (h)	n	4	6
	Median	0.167	0.167
	CV%	40.0	54.8
K_{el} (1/h)	n	0	5
	Geo. Mean	N/C	2.34
	CV%	N/C	33.2
$T_{1/2}$ (h)	n	0	5
	Geo. Mean	N/C	0.296
	CV%	N/C	31.4
AUC_{last} (h*ng/mL)	n	4	6
	Geo. Mean	5.60	51.4
	CV%	91.7	46.7
AUC_{all} (h*ng/mL)	n	4	6
	Geo. Mean	5.60	51.4
	CV%	91.7	46.7
AUC_{0-inf} (h*ng/mL)	n	0	5
	Geo. Mean	N/C	69.5
	CV%	N/C	40.1
$AUC_{\%extrap}$ (%)	n	0	5
	Geo. Mean	N/C	20.4
	CV%	N/C	38.9

14 subjects were excluded from PK set: 6 subjects in placebo group and 8 subjects in active treatment groups which did not have detectable CpG ODN D35 concentration in plasma (as per SAP)

Adverse Events:

System Organ Class Preferred Term	Severity	Number (%) of Subjects Placebo (N=6)	Cohort 1: 7.5mg CpG ODN D35 (N=6)	Cohort 2: 22.5mg CpG ODN D35 (N=6)	Cohort 3: 67.5mg CpG ODN D35 (N=6)	CpG ODN D35 Overall (N=18)	Overall (N=24)
GASTROINTESTINAL DISORDERS	MILD	0 (0.0)	1 (16.7)	1 (16.7)	0 (0.0)	2 (11.1)	2 (8.3)
DYSPEPSIA	MILD	0 (0.0)	1 (16.7)	0 (0.0)	0 (0.0)	1 (5.6)	1 (4.2)
NAUSEA	MILD	0 (0.0)	0 (0.0)	1 (16.7)	0 (0.0)	1 (5.6)	1 (4.2)
GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS	MILD	0 (0.0)	6 (100.0)	3 (50.0)	5 (83.3)	14 (77.8)	14 (58.3)
	MODERATE	0 (0.0)	0 (0.0)	3 (50.0)	1 (16.7)	4 (22.2)	4 (16.7)
FATIGUE	MILD	0 (0.0)	0 (0.0)	0 (0.0)	1 (16.7)	1 (5.6)	1 (4.2)
INJECTION SITE REACTION	MILD	0 (0.0)	6 (100.0)	3 (50.0)	5 (83.3)	14 (77.8)	14 (58.3)
	MODERATE	0 (0.0)	0 (0.0)	3 (50.0)	1 (16.7)	4 (22.2)	4 (16.7)
PYREXIA	MILD	0 (0.0)	0 (0.0)	0 (0.0)	1 (16.7)	1 (5.6)	1 (4.2)
MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS	MILD	0 (0.0)	0 (0.0)	0 (0.0)	1 (16.7)	1 (5.6)	1 (4.2)
	MODERATE	0 (0.0)	0 (0.0)	0 (0.0)	1 (16.7)	1 (5.6)	1 (4.2)
BACK PAIN	MILD	0 (0.0)	0 (0.0)	0 (0.0)	1 (16.7)	1 (5.6)	1 (4.2)
MYALGIA	MODERATE	0 (0.0)	0 (0.0)	0 (0.0)	1 (16.7)	1 (5.6)	1 (4.2)
NERVOUS SYSTEM DISORDERS	MILD	0 (0.0)	1 (16.7)	0 (0.0)	0 (0.0)	1 (5.6)	1 (4.2)
	MODERATE	0 (0.0)	1 (16.7)	0 (0.0)	1 (16.7)	2 (11.1)	2 (8.3)
HEADACHE	MILD	0 (0.0)	1 (16.7)	0 (0.0)	0 (0.0)	1 (5.6)	1 (4.2)
	MODERATE	0 (0.0)	1 (16.7)	0 (0.0)	1 (16.7)	2 (11.1)	2 (8.3)
RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS	MILD	0 (0.0)	0 (0.0)	1 (16.7)	0 (0.0)	1 (5.6)	1 (4.2)
NASAL CONGESTION	MILD	0 (0.0)	0 (0.0)	1 (16.7)	0 (0.0)	1 (5.6)	1 (4.2)
SKIN AND SUBCUTANEOUS TISSUE DISORDERS	MILD	0 (0.0)	1 (16.7)	0 (0.0)	0 (0.0)	1 (5.6)	1 (4.2)
PAIN OF SKIN	MILD	0 (0.0)	1 (16.7)	0 (0.0)	0 (0.0)	1 (5.6)	1 (4.2)

A subject with multiple occurrences of an AE is counted only once at the maximum severity within a SOC, PT and treatment group.
Percentages will be calculated from the number of subjects in the Safety Set within a treatment group.
MedDRA version 24.0